Part I Overview Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughou...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001829126-26-002860 | EDGAR | 109K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001829126-25-009210 | EDGAR | 23K words |
| 2025-08-18 | 2025-06-30 | 0001829126-25-006431 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001829126-25-003527 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001829126-26-003165 | EDGAR | 1K words |
| 2026-03-23 | 0001829126-26-002610 | EDGAR | — |
| 2026-03-17 | 0001829126-26-002331 | EDGAR | — |
| 2026-03-06 | 0001829126-26-002020 | EDGAR | — |
| 2026-03-04 | 0001829126-26-001927 | EDGAR | — |
| 2026-03-03 | 0001829126-26-001885 | EDGAR | — |
| 2026-02-27 | 0001829126-26-001755 | EDGAR | — |
| 2026-01-29 | 0001829126-26-000757 | EDGAR | — |
| 2025-12-17 | 0001829126-25-010101 | EDGAR | — |
| 2025-12-05 | 0001829126-25-009754 | EDGAR | — |
55 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001979414 |
| Ticker | NTHI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.neonc.com |
| Listed | 2025-03-26 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report